Skip to content


Beovu (brolucizumab) is an antibody pharmaceutical. Brolucizumab was first approved as Beovu on 2019-10-07. It is used to treat wet macular degeneration in the USA. It has been approved in Europe to treat wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.
Trade Name Beovu
Common Name Brolucizumab
Indication wet macular degeneration
Drug Class Monoclonal antibodies: humanized, cardiovascular indications
Get full access now